a , Comparison of proteomics data from BSO treated HeLa cells and SLC25A39/40 double knockout Jurkat cells
December 20 Product: Novo Nordisks Alhemo Indication: Adults and children aged 12 and up with hemophilia A or B Following an FDA rejection last year, Novo Nordisks Alhemo has received the regulators greenlight for preventing bleeding episodes or reducing their frequency in adults and children aged 12 and up with hemophilia A or B who have developed inhibitors, which are antibodies that neutralize clotting factors such as factor VIII or factor IX
Radha BN, Channakeshava BC, Nagaraj H, Pandurange Gowda KT, Bhanuprakash K, Ramachandrappa BK, Munirajappa R (2014) Effect of seed ageing on protein quality and quantity in maize
Advancements in microneedle technology: current status and next-generation innovations
Weight Loss Support: B12 injections are sometimes used as part of weight loss programs, although they are not a standalone solution for weight management